A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

This study is testing a new drug called B013 in combination with paclitaxel (a chemotherapy) for women with ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum-based chemotherapy and is considered platinum-resistant. **You may be eligible if...** - You have ovarian cancer, fallopian tube cancer, or primary peritoneal cancer confirmed by biopsy - Your cancer meets the criteria for platinum-resistant recurrence (it came back during or shortly after platinum-based chemotherapy) - Your general health is good (ECOG 0–1) and your expected survival is more than 12 weeks - You have at least one measurable tumor lesion - Your major organ functions (blood counts, liver, kidney, heart) are within acceptable ranges - You agree to use reliable contraception if you are of childbearing age **You may NOT be eligible if...** - You have received certain prior treatments excluded by the study protocol - You are currently using anti-tumor traditional Chinese herbal patent medicines - You have active serious infections or other significant health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.